MODIFICATION TO BLOOD GLUCOSE MONITORING SYSTEM

K012014 · Abbott Diabetes Care, Inc. · NBW · Dec 5, 2001 · Clinical Chemistry

Device Facts

• Record ID: K012014
• Device Name: MODIFICATION TO BLOOD GLUCOSE MONITORING SYSTEM
• Applicant: Abbott Diabetes Care, Inc.
• Product Code: NBW · Clinical Chemistry
• Decision Date: Dec 5, 2001
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1345
• Device Class: Class 2
• Attributes: Pediatric

Intended Use

The TheraSense FreeStyle Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh whole capillary blood. The FreeStyle System is intended for use outside the body (in vitro diagnostic use) by health care professionals and people with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for use in the diagnosis of or screening for diabetes mellitus and it is not intended for use on neonates or with arterial blood samples.

Device Story

System comprises handheld meter, electrochemical biosensor test strips, and quality control solution. User inserts strip; meter activates. Capillary action fills strip chamber with 0.3 microliters of blood from finger or alternative sites (forearm, upper arm, thigh, calf, hand). Glucose reacts with glucose dehydrogenase enzyme, generating electrical current proportional to glucose concentration. Meter measures current; displays result on LCD in 15-45 seconds. Used by healthcare professionals or patients at home for diabetes management. Provides quantitative glucose data to inform clinical decision-making regarding diabetes control.

Clinical Evidence

No clinical data provided; submission focused on labeling changes for alternative site testing.

Technological Characteristics

Electrochemical biosensor; glucose dehydrogenase enzyme-based sensing. Handheld meter with LCD. Requires 0.3 microliter sample volume. Capillary action fill. Connectivity: None specified. Sterilization: Not applicable.

Indications for Use

Indicated for quantitative glucose measurement in fresh whole capillary blood for individuals with diabetes mellitus to monitor diabetes control effectiveness. Indicated for use on finger, forearm, upper arm, thigh, calf, and hand. Contraindicated for neonates and arterial blood samples; not for diagnosis or screening of diabetes.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

• FreeStyle Blood Glucose Monitoring System (K992684, K994433)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image shows the logo for Therasense. The logo features a stylized human figure with outstretched arms, forming the letter 'S'. To the right of the figure is the word "THERASENSE" in bold, sans-serif font. Below the company name is the tagline "The Technology of Caring" in a smaller font.

DEC 0 5 2001

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: K012014

## 1. Device Name

| Classification Name: | Glucose Test System (§ 862.1345) |
|----------------------|---------------------------------------------|
| Common/Usual Name: | Blood Glucose Meter and Reagent Test Strips |
| Proprietary Names: | FreeStyle™ Blood Glucose Monitoring System |

## 2. Legally Marketed Devices to which Substantial Equivalence is Claimed:

| Predicate Device | 510(k) number |
|-------------------------------------------|------------------|
| FreeStyle Blood Glucose Monitoring System | K992684, K994433 |

## 3. Device Description

The FreeStyle Blood Glucose Monitoring System comprises an electrochemical biosensor glucose reagent test strip, a handheld meter, a quality control solution, a complete Owner's Booklet, a Quick Reference Guide and a "Getting Started" guide. A lancing device, lancets and a logbook for recording test results are also included with the system.

When the user inserts a test strip, the meter turns on. The user acquires a blood sample (with the test strip in the meter) by picking up the meter and touching the edge of the test strip at the sample target area, filling the chamber on the strip by capillary action. The meter sounds a tone

{1}------------------------------------------------

(beeps) to let the user know that the sample chamber is full and the reaction has begun. When the test is complete, the meter displays the glucose reading on its liquid crystal display (LCD).

## 4. Intended Use of the Device

The TheraSense FreeStyle Blood Glucose Monitoring System is intended to be used for the quantitative measurement of glucose in fresh whole capillary blood. The FreeStyle System is intended for use outside the body (in vitro diagnostic use) by health care professionals and people with diabetes at home as an aid to monitor the effectiveness of diabetes control. It is not intended for use in the diagnosis of or screening for diabetes mellitus and it is not intended for use on neonates or with arterial blood samples.

## 5. Principle of Operation

The user obtains a blood sample from the forearm, upper arm, finger, hand, calf or thigh. The user inserts a test strip into the meter, which turns the meter on. When the strip is touched to the blood drop, the sample chamber on the strip fills by capillary action in approximately 2 seconds. The blood sample volume required is approximately 0.3 microliters (300 nanoliters), which can be obtained from the finger or other areas of the body such as the arm, thigh, and hand. Test results are displayed in about 15 seconds. The time required to display test results varies depending on the blood glucose concentration (approximately 15 to 45 seconds).

The glucose in the blood sample reacts with the glucose dehydrogenase enzyme to yield gluconolactone, and produces a small electrical current. This current is measured by the FreeStyle meter and displayed as a glucose level.

## 6. Summary of Data Demonstrating Substantial Equivalence

This 510(k) included changes to the product labeling to add precautions and information about alternative site testing. There are no changes to the product or the intended use.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the bird-like figure. The logo is black and white.

# DEC 0 5 2001

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Eve A. Conner, Ph. D. Vice President, Quality Assurance and Regulatory Affairs Therasense, Inc. 1360 South Loop Road Alameda, CA 94502

Re: k012014

Trade/Device Name: FreeStyle™ Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose Test System Regulatory Class: Class II Product Code: NBW, LFR Dated: November 5, 2001 Received: November 6, 2001

### Dear Dr. Conner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket I nus lotter will and h you ding of substantial equivalence of your device to a legally marketed notheation. The I Drivinently sification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small monifacturers International and Consumer Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/odrh/dsma/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# INDICATIONS FOR USE STATEMENT

#### 510(k) Number: 012014

Device Name: FreeStyle Blood Glucose Monitoring System

## Indications for Use:

The TheraSense Inc. FreeStyle™ Blood Glucose Monitoring System is intended for use I he TheraSellse Inc. Freebire - Broom in whole blood. It is intended for use by in the qualitiative measurement of grith diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. It is not intended for the montoning the enectiveness of a classes mellitus, and it is not intended for use on neonates or arterial blood.

The FreeStyle Blood Glucose Monitoring System is specifically indicated for use on the finger, forearm, upper arm, thigh, calf and hand. 114 "

| (Division Sign-Off) | |
|-----------------------------------------|--------|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K12014 |

## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use

OR

Over-the-Counter Uses

(Per 21 CFR 801.10)